Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus dalteparin for thromboprophylaxis in bone marrow transplant recipients
IRCT20100127003210N25Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in thrombosis comparing Apixaban with Dalteparin (2 arms). Primary endpoints: Incidence of thrombosis and Incidence of bleeding. Started Jan 2022; status: completed.
02
Drugs
apixabandalteparin
03
Conditions
thrombosis
Beyond the preview
Go deeper on IRCT20100127003210N25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100127003210N25.